Hakan Kartal

Hakan Kartal

Auto-generated profile, based on publicly available information

Hakan Kartal

Gulhane Medical Faculty, Gulhane Education and Research Hospital, Department of Cardiovascular Surgery, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
AKAyşegül Küçük
Ayşegül Küçük
YPYücel Polat
Yücel Polat
AKAydan Kılıçarslan
Aydan Kılıçarslan
NSNuran Süngü
Nuran Süngü
HKHakan Kartal
Hakan Kartal
Mustafa ArslanMustafa Arslan
Mustafa Arslan
Aim: The aim of this study was to evaluate the effects of irisin in a murine model of hind limb ischemia reperfusion (I/R). Methods: The mice were divided into four groups (n = 6 in each group): control, irisin, ischemia reperfusion (I/R), and irisin-ischemia reperfusion (I–I/R). Irisin (0.5 μg.g− 1, intraperitoneally [i.p.]) was administered 30 min before the I/R procedure. After 2 h of ischemia and 2.5 h of reperfusion, blood and tissue samples were taken for biochemical and histopathological analysis. The results were analyzed by Kruskal–Wallis and Mann–Whitney U-tests. Results: There was a statistically significant difference in the total antioxidant status (TAS) and total oxidant status (TOS) levels in all the groups. The TAS level in the I/R group was significantly lower than that in the control, irisin, and I–I/R groups, whereas the TOS level was significantly higher in the I/R group as compared with that in the other groups. Caspase-3 activity and caspase-8 activity, indicators of inflammation, were significantly higher in the I/R and I–I/R groups as compared with those in the control and irisin groups. Conclusion: Irisin may have protective effects in skeletal muscle ischemia reperfusion injury.